AI Momentum, Policy-Driven Thematics, and the Valuation Squeeze: Alpha Research Weekly Digest (Feb 23 – Mar 2, 2026)

Week's dominant investment themes

1. AI as the organizing macro-story. Semiconductor foundries (TSM), GPU leadership (NVDA), AI-focused OEMs (AMD, SMCI), and high-margin systems/platform suppliers (AVGO) were central narratives. Several research notes emphasized large, multi-quarter revenue tailwinds tied to hyperscaler procurement and enterprise AI deployments.

2. Cloud + enterprise AI monetization. Cloud incumbents and software vendors (AMZN/AWS via the OpenAI deal, CRM, ORCL, SNOW, PLTR) are positioning to convert infrastructure demand into recurring, higher-margin revenue — but analysts flagged execution sensitivity and high multiples.

3. Event / policy-driven value trades. Media M&A chatter (WBD/Paramount Skydance), U.S. cannabis rescheduling speculation (MSOS, CURLF, TLRY), and equity issuance or dilution (NEE $2B equity units) created event-risk-driven upside scenarios.

4. Income and capital-allocation tradeoffs. Many notes highlighted dividend and buyback stories as stabilization anchors: XOM, NEE, CMCSA, VZ, DOW, UWMC and large banks (JPM, WFC) were assessed on yield plus execution dynamics.

5. The valuation cross-current. Across sectors, research teams balanced strong fundamentals vs. stretched multiples — classic examples include NVDA and LLY (premium growth priced in) versus CMCSA and PYPL (value/multi compression).

Concise summaries — each research piece (headlines, key metric and one-line synthesis)

Note: Price and metrics are the published values in each note. Stance reflects the analyst view provided.

• MSOS: Cannabis ETF, Policy Catalyst Ahead — Current Price $3.88; 52-week range $2.02–$7.25. NEUTRAL. A concentrated, high-volatility U.S. cannabis play that would re-rate on federal rescheduling but remains headline-sensitive.

• DKNG: Growth vs Guidance, Neutral View — $23.84; Market Cap $11.75B. NEUTRAL. Revenue and footprint expansion balanced by cautious guidance and analyst target trims.

• MRK: Pipeline Wins and Restructure Support Upside — $123.82; P/E 16.77. BULLISH. Positive Phase 3 oncology data and organizational split support upside while KEYTRUDA patent timing is the main risk.

• COST: Membership Moat, Valuation Caution — $1,010.79; P/E 54.04. NEUTRAL. High-quality retail moat but premium valuation constrains near-term upside.

• WFC: Valuation, AI Integration, and Reputation Risk — $81.45; P/E 12.51. NEUTRAL. Attractive valuation and AI initiatives offset by reputation headlines and execution risk.

• MA: Mastercard — Payments Growth & Crypto Push — $517.21; Trailing P/E 30.82. BULLISH. Strong secular payments growth and product innovation (e.g., MetaMask card) support upside, but size positions carefully.

• V: Payments Growth & Global Expansion — $320.14; P/E 29.03. BULLISH. Franchise strength, Latin America expansion, and durable network effects underpin growth.

• DOW: Restructuring, Yield, and Mixed Fundamentals — $30.73; Dividend Yield 4.56%. NEUTRAL. High income but negative EPS and weak ROE make the case execution-dependent.

• NEE: Growth, Yield, Dilution Tradeoff — $93.77; P/E 28.59. BULLISH. Renewable growth engine with dilution risk from $2B equity units issuance.

• CMCSA: Value, Yield, and Industry Crosswinds — $30.96; P/E 5.57; Dividend 4.26%. NEUTRAL. Deep multiple and attractive yield tempered by leverage and secular media risks.

• KR: Kroger, Reset, Valuation, Risks — $68.24; Forward P/E ~12.9. NEUTRAL. New CEO and digital pushes are positive; margin and competition risks persist.

• CRM: AI Push and Buybacks, Key Outlook — $194.79; P/E 24.48. NEUTRAL. AI monetization (Agentforce), buybacks and recurring revenue are positives; valuation is sensitive to execution.

• WBD: Takeover Talk Powers Upside — $28.17; P/E 92.96. BULLISH. Takeover whispers (large Paramount Skydance bid) create a material upside event though streaming fundamentals are weak.

• SNOW: Snowflake, AI Growth vs Rich Valuation — $168.41; Market Cap $57.63B. NEUTRAL. Strong enterprise adoption for data/AI but negative trailing profitability and stretched multiples.

• VZ: 5G Growth and High Dividend, Neutral View — $50.14; Dividend Yield 6.36%. NEUTRAL. High income and 5G initiatives tempered by leverage and capex needs.

• TGT: Dividend Income Meets Valuation, But Near-Term Risks Persist — $113.79; Dividend 4.01%. NEUTRAL. Income appeal and ROE balanced against near-term earnings headwinds.

• FDX: Strategy, Tariffs, and Fair Value — $387.00; P/E 20.98. NEUTRAL. Margin improvement and international push offset tariff refund lawsuits and legal uncertainty.

• GM: EV Momentum and Cyclical Upside — $78.71; Mean PT $94.62. BULLISH. Cyclical recovery + EV optionality, but execution is key.

• CAT: Riding AI & Infra Momentum — $742.83; ROE 45.15. BULLISH. Re-rating from AI-infrastructure demand and large backlog; valuation elevated.

• TSM: TSMC Outlook — Scale, AI Demand, Valuation — $374.58; P/E ~29. BULLISH. Foundry leadership and AI-driven capacity demand support structural upside; geopolitical risk noted.

• CURLF: Curaleaf — Earnings Beat, High-Volatility Opportunity — $2.33; Market Cap $2.47B. NEUTRAL. Q4 beat but still loss-making and high beta.

• JNJ: Quality Pharma with Oncology Momentum — $248.43; P/E 22.34. NEUTRAL. Oncology growth and cash flow offset litigation overhang.

• TLRY: Valuation vs. Volatility — $7.87; Price/Sales 0.91. NEUTRAL. Cheap on sales/book with high volatility and negative EPS.

• KO: Defensive Growth & Dividend Outlook — $81.56; P/E 26.76. NEUTRAL. Durable brand, low beta; near-term upside limited.

• JPM: Bank Strength with Valuation Support — $300.30; P/E 14.20. BULLISH. Diversified bank with earnings power; watch regulatory headlines.

• XOM: Oil Upside Amid Geopolitical Tailwinds — $152.50; Dividend 3.48%. BULLISH. Integrated presence, strong cash flow; geopolitics can swing returns.

• BA: Demand Strength, Valuation Watch — $227.53; P/E 79.95. BULLISH. Fleet renewal and widebody orders support upside; valuation and geopolitics are risk anchors.

• PYPL: Valuation vs Execution Risk — $46.21; P/E 8.13. NEUTRAL. Cheap on P/E yet faces lawsuits and leadership transition risks.

• BABA: Alibaba outlook — growth, AI, and margin play — $144.11; P/E 16.82. BULLISH. Diversified ecosystem with AI and cloud investment upside.

• SLS: REGAL Momentum and Clinical Upside — $4.93; Market Cap $0.70B. BULLISH. REGAL trial approaching OS trigger; binary clinical risk dominates.

• BLDR: Value, Tech Push, Housing Sensitivity — $104.29; Forward P/E ~17.5. NEUTRAL. Housing sensitivity and margin recovery timing matter.

• UWMC: High Yield, High Risk Mortgage Play — $4.41; Dividend Yield 9.62%. NEUTRAL. Attractive yield but EPS miss and liquidity sensitivity to mortgage rates.

• NKE: Brand Strength vs China Headwinds — $62.18; P/E 36.47. NEUTRAL. Durable brand but China distributor stress and rich multiple.

• RIOT: Crypto Sensitivity Meets Analyst Optimism — $16.29. NEUTRAL. BTC correlation drives earnings volatility; operational scale supports margin upside when BTC rallies.

• MSTR: Bitcoin Bet, Volatility & Valuation — $129.50. NEUTRAL. Hybrid software + large BTC balance sheet; impairments create earnings lumpiness.

• SMCI: AI Demand vs Valuation — $32.39; P/E 22.23. NEUTRAL. MicroBlade server demand and guidance raise; tariff and margin risk persist.

• AI (C3.ai): Bearish Near 52-Week Low — $7.95. BEARISH. Weak fundamentals and consensus Sell; upside contingent on converting partnerships to recurring revenue.

• NIO: EV growth vs profitability — $4.87. NEUTRAL. Delivery expansion and GeniTech investment balanced by negative EPS and liquidity constraints.

• CVNA: Growth vs Valuation Snapshot — $334.16; P/E 51.98. NEUTRAL. Record revenue but rate sensitivity and rich multiples.

• SOFI: Growth vs Valuation, Neutral View — $17.76; P/E 47.06. NEUTRAL. Multi-product fintech growth but high valuation sensitivity.

• HOOD: Profitability vs Valuation Debate — $75.85; P/E 36.3. NEUTRAL. Now profitable with robust retail base; valuation prices sustained growth.

• INTC: Intel’s Turnaround or Transition? — $45.61; Forward P/E 88.5. NEUTRAL. Strategic reset and foundry investments with execution risk and high capex.

• ORCL: Cloud + AI Growth vs Legal and Valuation Overhang — $145.40; ROE 67.59. NEUTRAL. Strong cloud traction but pending AI disclosure litigation and March 9 earnings risk.

• AVGO: AI Chips vs Valuation Risk — $319.55; Trailing P/E >60. NEUTRAL. 2nm AI SoC and high FCF, but multiples reflect a lot of good news.

• AMD: AI Deal Boosts Data Center Thesis — $200.21; Forward P/E 29.85. BULLISH. Large Meta AI chip deal validates data-center roadmap.

• AMZN: AI Deal Spurs Growth Thesis — $210.00; P/E 29.02. BULLISH. $50B OpenAI enterprise partnership reframes AWS growth and margin outlook.

• PLTR: Positioned at Center of AI Growth — $137.19; P/E 201.91. NEUTRAL. Strong positioning in regulated AI deployments but premium multiple.

• GME: Strategy, M&A Ambition, and Valuation — $24.03; Current Ratio 10.39. NEUTRAL. Cash-rich and acquisitive with high optionality and sell-side skepticism.

• LLY: Growth, GLP-1 Momentum, and Premium Valuation — $1,051.99; P/E 48.09. BULLISH. Oral GLP-1 phase 3 wins underpin premium long-term growth.

• NVDA: AI Growth vs Valuation — $177.19; Market Cap $4.31T. BULLISH. GPU leadership and software ecosystem create durable growth; valuation stretched but forward-adjusted multiples show room.

• LOW: Steady Growth, Limited Upside — $280.36; P/E 23.2. NEUTRAL. Predictable cash flow, capital returns; limited near-term upside.

• MSOS (repeat): US Cannabis ETF Outlook — $3.77; AUM ~$190M. NEUTRAL. Thematic and risky; size tactically.

• DKNG (repeat): DraftKings — $22.31. NEUTRAL. Q4 beat; guidance cautions.

• ABNB: Travel Momentum vs Valuation — $127.89; ROE 32.14. NEUTRAL. Secular travel demand but mixed near-term signals.

• MRK (repeat): $122.26; P/E 16.62. BULLISH. Oncology momentum and dividend.

• COST (repeat): $985.27; P/E 52.68. NEUTRAL. Membership moat, priced for perfection.

• MA (repeat): $526.41; P/E 31.36. BULLISH. Durable payments growth.

• V (repeat): $320.95; ROE 54.22. BULLISH. LatAm acquisition expands addressable market.

• IONQ: Quantum Upside, Execution Risk — $31.90; Market Cap $11.3B. NEUTRAL. Trapped-ion differentiate but legal probe and SkyWater acquisition risk.

• DOW (repeat): $30.52; Dividend 4.59%. NEUTRAL. Restructuring narrative.

• NEE (repeat): $92.18; Dividend 2.72%. NEUTRAL. Renewable leader priced near highs.

• CMCSA (repeat): $31.34; P/E 5.64. NEUTRAL. Broadband + advertising narrative.

• KR (repeat): $66.36; Forward P/E ~13.1. BULLISH. Reset under new CEO.

• WBD (repeat): $28.75; P/E 142.33. NEUTRAL. M&A-driven upside but regulatory friction.

• SNOW (repeat): $172.50; Market Cap $59.03B. NEUTRAL. Pullback creates potential entry for long-term AI believers.

• TGT (repeat with slightly different metrics): $116.69; P/E 14.04. NEUTRAL. Income and stability.

• FDX (repeat bullish note): $388.48; EPS (TTM) $18.14. BULLISH. Restructuring momentum and planned freight spin-off.

• CAT (repeat): $759.74; P/E 39.79. BULLISH. AI infrastructure demand is visible.

• TSM (repeat): $370.54; P/E 28.91. BULLISH. Foundry cycle and April earnings are key anchors.

• JNJ (repeat): $242.49; P/E 21.8. NEUTRAL. Defensive buy with biotech upside.

• TLRY (repeat): $7.75; Market Cap $0.90B. NEUTRAL. Carlsberg licensing diversification.

• JPM (repeat bullish): $310.79; P/E 14.69. BULLISH. Diversified bank ready for long-term upside.

• XOM (repeat): $147.28; Dividend 3.48%. NEUTRAL. Cash flow leader, near-term limited upside.

(End of per-note summaries.)

Patterns, cross-currents and connections across the week’s research

1. Concentration of bullish views where AI demand is explicit and contract-backed. AMD (Meta deal), AMZN (OpenAI), and NVDA show the clearest examples where customer commitments (or large strategic investments) materially de-risk future revenue. Research teams consistently upgraded conviction where durable multi-year contracts or enterprise partnerships were documented.

2. Valuation debate is pervasive. Nearly every bullish AI cloud/hardware name is tempered by a valuation caveat. Analysts repeatedly framed decisions as: buy-on-dip for conviction investors, wait-for-confirmation for risk-conscious allocators.

3. Income and event-driven trades coexist. Heavy-capital and cyclical names (XOM, NEE, DOW, CMCSA) are pitched as dividend anchors while event-driven names (WBD, MSOS, SLS) require binary outcome sizing.

4. Regulatory and legal risk as a first-order cross-section. From cannabis rescheduling to AI disclosure suits (ORCL) and tariff/class action exposure (FDX), analysts placed legal/regulatory risk on the same footing as macro or execution risk.

5. Repeated “repeat notes” reflect evolving narratives: several tickers received multiple briefings in the week with consistent core views but updated short-term catalysts (e.g., FDX, MRK, COST, TSM, SNOW). This signals active monitoring rather than static coverage.

Contrarian and distinctive perspectives worth noting

• WBD: Several notes flag a bullish takeover scenario despite weak streaming fundamentals. That is a classic event-driven contrarian: fundamentals poor, but deal outcomes could re-rate the equity materially.

• Cannabis (MSOS, CURLF, TLRY): Coverage is unusually balanced — while thematic upside from federal policy is acknowledged, analysts urge tactical sizing because liquidity and execution risks are high. The contrarian angle is that small policy shifts could be a disproportionate re-rating catalyst.

• AI software names with weak fundamentals (C3.ai): The research team is explicitly bearish, contrasting with pervasive AI enthusiasm. They argue that execution and recurring revenue matter more than narrative exposure.

• Value in legacy media/telecom: CMCSA’s deep multiple compression makes it a defensive income play for contrarian income-focused portfolios even as secular headwinds continue.

Methodology and data-driven insights: how Alpha Research is evaluating opportunities

1. Multi-factor framework: Analysts consistently combine (a) catalytic event risk (earnings, M&A, trials), (b) structural secular tailwinds (AI, renewables), (c) capital allocation (buybacks/dividends/equity issuance), and (d) legal/regulatory overlays. Ratings reflect an explicit weighting of these vectors.

2. Signal hierarchy: For growth names, contracted revenue or multi-year customer commitments increase conviction materially (e.g., AMD–Meta deal, AMZN–OpenAI). For cyclicals, backlog, order books and backlog-to-revenue ratios (CAT, BA) are emphasized.

3. Valuation context: Analysts use forward multiples, PEG ratios, cash-flow yield, and scenario-based DCFs. Where headline multiples are rich, teams model base, bull, and bear scenarios and provide tactical guidance (size, buy-on-dip, wait-for-confirmation).

4. Event-driven analytics: For binary outcomes (clinical trials, M&A, policy), probability-weighted returns and implied takeover premiums are quantified — WBD notes explicitly calculate upside to a reported $111B bid scenario.

5. Liquidity and balance-sheet stress-testing: For small-cap, high-yield, or leverage-sensitive names (UWMC, NIO, TLRY), research runs short-term liquidity stress tests tied to interest-rate and margin scenarios.

Practical investment implications

• For growth at scale: Allocate to leaders with contract visibility and strong free-cash-flow conversion (NVDA, AMZN, AMD, TSM), but manage position size to account for valuation shock risk.

• For income and defensive allocation: Consider dividend anchors (XOM, JPM, VZ, CMCSA) for yield and downside protection; be watchful of dividend sustainability where EPS is negative (DOW, UWMC).

• Thematic/ event risk plays: Size these as satellite positions — MSOS (cannabis policy), WBD (M&A), SLS (biotech trial trigger) — where asymmetric outcomes are possible but binary risks are high.

• Fintech & payments: MA and V remain core growth-quality names; PYPL and HOOD present differentiated risk/reward where valuation and legal/regulatory clarity should dictate entry.

• Be wary of narrative-only AI exposure: Names without durable revenue conversion (C3.ai) merit a skeptical stance despite category enthusiasm.

Acknowledging uncertainty and diverging viewpoints

Alpha Research staff explicitly flagged multiple sources of forecast variance: geopolitical risk (oil, defense orders), policy (cannabis, antitrust M&A), legal outcomes (AI disclosure suits, tariffs), and macro sensitivity (rates impacting mortgage-originators and used-car financiers). Where consensus tilts bullish, there is frequent caveat language about valuation sensitivity and timing risk.

Research agenda & watchlist for next week

1. Oracle (ORCL) March 9 earnings and the trajectory on AI disclosure litigation — this will be an immediate read-through on enterprise AI legal risk and backlog conversion.

2. Semiconductor supply signals and TSMC capacity commentary — watch the April 15 earnings placeholder mentioned in coverage for guidance shifts; any comments on node ramp schedules will propagate across NVDA/AMD/AVGO/SMCI.

3. WBD/Paramount Skydance takeover developments and any regulatory filings — even rumor resolution can swing the equity materially.

4. Cannabis policy signals — Senate/House activity, DOJ statements, or FDA guidance that could change the probability weighting for MSOS/CURLF/TLRY.

5. Biotech trial triggers: REGAL final OS trigger for Sellas (SLS) and any near-term readouts that could be binary re-rating events.

6. Macro and rate-driven signals: March data prints and Fed commentary that will affect mortgage-sensitive names (UWMC), banks (JPM, WFC), and high-duration software names (SNOW, CRM).

7. FDX tariff/refund legal updates and DOW restructuring execution — legal filings or class-action developments could alter near-term cash expectations.

8. AI partnership execution and enterprise customer commentary from AMZN (OpenAI integration path) and AMD (Meta supply sequencing) to see how contracted revenue converts into bookings and procurement cadence.

Closing synthesis

This week’s research cycle reinforced a central truth for 2026 portfolios: the intersection of AI-driven demand and corporate execution is where the largest asymmetric returns appear — but that same intersection concentrates valuation risk. Investors should distinguish between (a) names with visible, contract-backed revenue and balance-sheet resilience (NVDA, AMZN, AMD, TSM) and (b) narrative-exposed names whose value depends on converting large but uncontracted opportunity sets (many AI-software names). Parallel to the tech-driven themes are durable income and event-driven trades that can stabilize portfolios or provide high-upside optionality — but each requires disciplined sizing and scenario-based risk management.

We will watch next week’s corporate headlines with particular attention to contract conversions, legal and regulatory developments, and any new event catalysts (M&A, trials, policy) that will re-prioritize risk/reward across the Alpha coverage universe.

— Alpha Research Editorial Team